Risk Factors That Increases Covid-19 Severity

Article Sidebar

PDF
Published: Feb 10, 2022
DOI: https://doi.org/10.47191/ijmscrs/v2-i2-02
Keywords:
COVID-19; coronavirus SARS-CoV-2; arterial hypertension; medication; vaccine; obesity, diabetes, age, risk factors.

Main Article Content

Mayte Fregoso
Department of Medicine, UAG College of Medicine, Guadalajara, Jalisco, México
María F. Laines
Department of Medicine, UAG College of Medicine, Guadalajara, Jalisco, México
José M. Zepeda
Department of Medicine, UAG College of Medicine, Guadalajara, Jalisco, México
Carlos A. López
Department of Medicine, UAG College of Medicine, Guadalajara, Jalisco, México
Félix Osuna
Department of Medicine, UAG College of Medicine, Guadalajara, Jalisco, México

Abstract

Introduction: The relation between some risk factors and its impact on COVID 19 progression was described; as well as the effectiveness of certain vaccines.


Material and methods: Recent articles from different digital platforms were consulted for this manuscript.


Results: Several studies have shown that some of the main risk factors for COVID 19 were age, hypertension and obesity.


Conclusion: From the studies reviewed in this article, it is concluded that hypertension is one of the aggravating factors in COVID 19 disease due to ACE receptors; vitamin D and the use of different vaccines were also discussed.

Article Details

How to Cite
Fregoso, M. ., María F. Laines, Zepeda , J. M. ., Carlos A. López, & Osuna, F. . (2022). Risk Factors That Increases Covid-19 Severity. International Journal of Medical Science and Clinical Research Studies, 2(2), 86–91. https://doi.org/10.47191/ijmscrs/v2-i2-02
Issue
Vol. 2 No. 2 (2022): Volume 02 Issue 02 February 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Swamy, S., A. Koch, C., Hannah-Shmouni, F., Schiffrin, E., Klubo-Gwiezdzinska, J., & Gubbi, S. (2021). Hypertension and COVID-19: Updates from the era of vaccines and variants. Journal Of Clinical & Translational Endocrinology, 1-7. doi:

https://doi.org/10.1016/j.jcte.2021.100285

II. Al-Sabah S, Al-Haddad M, Al-Youha S, Jamal M, Almazeedi S. COVID-19: Impact of obesity and diabetes on disease severity. Clinical Obesity. 2020;1-6.

III. Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertension Research.2020;43(10):1028-1046

IV. Galván-Tejada C, Zanella-Calzada L, Villagrana-Bañuelos K, Moreno-Báez A, Luna-García H, Celaya-Padilla J et al. Demographic and Comorbidities Data Description of Population in Mexico with SARS-CoV-2 Infected Patients(COVID19): An Online Tool Analysis. International Journal of Environmental Research and Public Health. 2020;17(14).

V. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-1720

VI. Salazar M, Barochiner J, Espeche W, Ennis I. COVID-19, hipertensión y enfermedad cardiovascular. Hipertensión y Riesgo Vascular. 2020;37(4):176-180.

VII. Ssentongo P, Ssentongo A, Heilbrunn E, Ba D, Chinchilli V. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLOS ONE. 2020;15(8):1-16.

VIII. Giralt Herrera A, Rojas Velázquez J, Leiva J. Relationship between COVID-19 and Arterial Hypertension. Revista Habanera de Ciencias Médicas [Internet]. 2020 [cited 5 November 2020];19(2):1-12. Available from: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3246/2494

IX. Reynolds H, Adhikari S, Pulgarin C, Troxel A, Iturrate E, Johnson S et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. New England Journal of Medicine. 2020;382(25):2441-2448.

X. Moreno-Montoya J. El desafío de comunicar y controlar la epidemia por coronavirus. Biomédica. 2020 [citado 05/11/2020];40(1):11-3. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-415720200001000 11&lng=en

XI. Carroll K, Hobden J, Miller S, Morse S, Mietzner T, Detrick B et al. Microbiología Médica. 27th ed. México, D.F: McGraw-Hill Education.; 2016

XII. Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020 [citado 05/11/2020];12. Disponible en:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156162/

XIII. Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL & Loscalzo J. (2018). Harrison. Principios de Medicina Interna. New York, NY: MC GRAW HIL.

GENERAL GUIDELINES ON REFERENCES

References should be numbered consecutively as they appear in the text. Reference citations in the text should be identified by numbers in superscript after the punctuation marks. All authors should be quoted for papers with up to six authors; for papers with more than six authors, the first six should be quoted followed by et al.

Journal article:

Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006;8(2):156-63.

Book chapter:

O'Brien C. Drug addiction and drug abuse. In: Brunton LB, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2005: 607-629.

Website:

National Cancer Institute. Fact sheet: targeted cancer therapies, 2012. Available at http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted#q1. Accessed 9 June 2014.